IL17A and psoriasis: Concerning IL-17 inhibitors, UNCOVER-2 and UNCOVER-3, two phase 3 trials which showed the efficacy and safety of ixekizumab for patients with moderate to severe psoriasis, reported four cases of CD and seven cases of UC compared to zero in the placebo-treated group [39].